Viral hepatitis

Current Opinion in Infectious Diseases

Volumn 12, Issue 5, 1999, Pages 481-490

  Trépo, Christian ^a   Zoulim, Fabien ^a   Pradat, Pierre ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN; VIRUS RNA;

HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; REVIEW; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0032785762     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199910000-00011     Document Type: Review

References (64)

1. 1 Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis 1998; 178:1579-1584. Outstanding large study from the CDC surveyed sentinel counties providing the best picture of hepatitis A epidemiology and prevention strategies in the USA.
2. 2 Craig AS, Sockwell DC, Schaffner W, Moore WL Jr, Skinner JT, Williams IT, et al. Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis 1998; 27:531-535.
3. 3 Bertino JS Jr, Thoelen S, VanDamme P, Bryan JP, Becherer PR, Frey S, et al. A dose response study of hepatitis A vaccine in healthy adults who are > or=30 years old and weigh > or=77 kg. J Infect Dis 1998; 178:1181-1184. This study showed in adults over 77 kg a dose dependent seroconversion, but after 2 injections all subjects seroconverted whatever the doses received.
4. 4 Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. Incidence of hepatitis B virus infection in the United States 1998; 178:954-959. Extremely important study providing convincing evidence that targeted HB vaccine strategies did not decrease the incidence of HBV infections between 1976-80 and 1988-94 confirming the need for expanded vaccination strategies.
5. 5 Gilson RJ, de Ruiter A, Waite J, Ross E, Loveday C, Howell DR, et al. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sex Transm Infect 1998; 74:110-115.
6. 6 Juárez-Figueroa L, Uribe-Salas F, Conde-Glez C, Hernández-Avila M, Olamendi-Portugal M, Uribe-Zún̄iga P, Calderón E. Low prevalence of hepatitis B markers among Mexican female sex workers. Sex Transm Infect 1998; 74:448-450.
7. 7 Quale JM, Landman D, Wallace B, Atwood E, Ditore V, Fruchter G. Nosocomial hepatitis B virus transmission and fingerstick monitoring. Am J Med 1998; 105:296-301. This elegant study confirms that unexpected nosocomial transmission may occur when stringent good practices including changes of glove are not observed.
8. 8 Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1993; 27:100-106.
9. 9 Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunised population. Clin Infect Dis 1998; 26:933-937.
10. 10 Silva AE, McMahon BJ, Parkinson AJ, Sjogren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998; 26:895-897. This study clarifies the heterogeneity of situations reflected by anti-HBc as a sole HBV marker with only 4% of cases exhibiting low level HBV DNA detected by conventional polymerase chain reaction.
11. 11 Thio CL, Carrington M, Marti D, O'Brien SJ, Vlahov D, Nelson KE, et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999; 179:1004-1006.
12. 12 Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284:825-829. Milestone study challenging the usually accepted concept that HBV clearance is lysis of infected cells and showing that cytokines may indeed eradicate the infection without killing cells.
13. 13 Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B antigen seroconversion. Hepatology 1999; 29:976-984.
14. 14 Brunette M, Giarin M, Oliveri F, Chiaberge E, Baldi M, Alfarano A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88:4186-4190.
15. 15 Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999; 179:775-782.
16. 16 Ferré-D'Amaré AR, Zhou K, Doudna JA. Crystal structure of a hepatitis delta virus ribozyme. Nature 1998; 395:567-574. New breakthrough of the determination of the three dimensional structure of ribozyme may have also very important implications in the future to design gene therapy approaches based on the use of ribozyme to cleave targeted RNA.
17. 17 Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68. Pivotal registration studies of a drug now approved as first line therapy as alternative to interferon with wider spectrum of indication including advanced liver disease.
18. 18 Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 1998; 178:1483-1487. One of the few existing studies which document for HBV the benefit of combining a nucleoside analogue with interferon.
19. 19 Pichoud C, Seignères B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and Famciclovir resistance. Hepatology 1999; 29:230-237. As for HIV, the results of this study demonstrate a direct correlation between a genotype and a resistant phenotype.
20. 20 Tang JH, Yeh CT, Chen TC, Hsieh SY, Chu CM, Liaw YF. Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. J Infect Dis 1998; 178:866-869.
21. 21 King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1998; 42:3179-3186. New very promising drug in vitro without cross resistance with lamivudine.
22. 22 Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrob Agents Chemother 1998; 42:3130-3135.
23. 23 Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998; 42:3209-3217.
24. 24 Hurwitz SJ, Tennant BC, Korba BE, Gerin JL, Schinazi RF. Pharmacodynamics of (-)-beta-2′,3′-dideoxy-3′-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans. Antimicrob Agents Chemother 1998; 42:2804-2809.
25. 25 World Health Organization, Weekly Epidemiological Record 1997; 72:65-72. Good overview of hepatitis C prevalence worldwide.
26. 26 HENCORE: Hepatitis C European Network for Co-Operative Research. Guidelines for control and management of hepatitis C. Report to the European Commission DG V: March 1998. Large collaborative study including eight European hepatology centres. Field studies conducted in different subgroups of general population report different prevalence rates in the different countries.
27. 27 Coppola RC, Masia G, Pradat P, Trepo C, Carboni G, Argiolas F, Rizzetto M. Impact of hepatitis C virus infection on healthy subjects of an Italian island. J Viral Hepatitis (in press). A high prevalence rate observed in elderly people in Sardinia suggests a common possible source of infection several decades ago.
28. 28 Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Mennitilppolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26:1006-1011.
29. 29 Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27:30-35. Geographical clusters with very high prevalence of hepatitis C infection suggest common source of infection.
30. 30 Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-1696.
31. 31 Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (Suppl 1):S11-S19. Prospective study on intravenous drug users showing that HCV infection occurs soon after initiation of drug abuse and supporting the need of wider legal access to sterile syringes.
32. 32 Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995; 15:209-212.
33. 33 Simon N, Couroucé AM, Lemarrec N, Trépo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46:504-511.
34. 34 Forns X, Fernandez-Llama P, Pons M, Costa J, Ampurdanes S, Lopez-Labrador FX, et al. Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. Nephrol Dial Transplant 1997; 12:736-740.
35. 35 La Torre A, Biadaioli R, Capobianco T, Colao MG, Monti M, Pulli F, et al. Vertical transmision of HCV. Acta Obstet Gynecol Scand 1998; 77:889-892.
36. 36 Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27:108-117.
37. 37 Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. J Infect Dis 1998; 177:1480-1488.
38. 38 Mele A, Stroffolini T, Tosti ME, Corona R, Santonastasi F, Gallo G, et al. Heterosexual transmission of hepatitis C in Italy. J Med Virol 1999; 57:111-113. Data from the Italian hepatitis surveillance system showing an association between the risk of HCV infection and the number of sexual partners.
39. 39 Rooney G, Gilson RJ. Sexual transmission of HCV infection. Sex Transm Infect 1998; 74:399-404.
40. 40 Comandini UV, Tossini G, Longo MA, Ferri F, Cuzzi G, Noto P, et al. Sporadic hepatitis C virus infection: a case-control study of transmission routes in a selected hospital sample of the general population in Italy. Scand J Infect Dis 1998; 30:11-15. First large case-control study on sporadic hepatitis C virus infection. This well-designed approach is the only reasonable way of detecting new potential risk factors.
41. 41 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832. First attempt to model progression of fibrosis in chronic hepatitis C which illustrates well the extreme differences in progression rates but has obvious limitations since progression is not linear.
42. 42 Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:351-355.
43. 43 Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351:1773-1777.
44. 44 Lunel F, Musset L. Hepatitis C virus infection and cryoglobulinemia. J Hepatol 1998; 29:848-855.
45. 45 Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129:294-298.
46. 46 Zignego AL, Ferri C, Giannini C, La Civita L, Careccia G, Longombardo G. et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997; 142:545-555.
47. 47 Zignego AL, Bréchot Ch. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999; 31:369-376. Updated review which aims at providing clues to the pathogenesis of HCV diseases.
48. 48 Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load. Viral genotype, and cell genotype. Blood 1998; 91:3841-3849. This study provides the most detailed documentation of links between genotypes and lymphotropism especially for 1b.
49. 49 Kato N, Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Shimotohno K. Hepatitis C virus population dynamics in human lymphocytes and hepatocytes infected in vitro. J Gen Virol 1998; 79:1859-1869.
50. 50 Mecchia M, Casato M, Tafi R, Fillocamo G, Bonomo L, Fiorilli M, et al. Nonrheumatoid IgM in human hepatitis C virus-associated type II cryoglobulinemia recognize mimotopes of the CD4-like LAG-3 protein. J Immunol 1996; 157:3727-3736.
51. 51 Zignego AL, Giannelli F, Marrochi ME, Giannini C, Gentilini P, Ferri C. Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol 1997; 15:711-712.
52. 52 Pileri P, Uematus Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-941. First description of a candidate HCV receptor which could account for some binding and neutralizing reactivity properties previously described as well as for tropism of HCV and B cell activation.
53. 53 Lenzi M, Frisoni M, Mantovani V, Ricci P, Muratori L, Francesconi R, et al. Haplotype HLA-B8-DR3 confers suceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91:2062-2066.
54. 54 Hayashi J, Kawakami Y, Nabeshima A, Kishihara Y, Furusyo N, Sawayama, et al. Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 1998; 43:384-391.
55. 55 Berenguer M, Wright TL. Hepatitis C virus. Adv. Gastroenterol Hepatol Clin Nutrition 1996; 1:2-21.
56. 56 Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107. Reference study modeling HCV kinetics and the impact of interferon therapy which confirms the rationale for higher and daily doses of interferon as previously advocated by Japanese studies, providing a clue for the many failures of interferon monotherapy as used so far.
57. 57 Prieto M, Berenguer M, Rayon JM, Cordoba J, Arhuello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256.
58. 58 McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492. See [60].
59. 59 Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. J. N Engl J Med 1998; 339:1493-1499. See [60].
60. 60 Poynard T, Marcellin P, Lee SS, Niederau C, Minik GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352:1426-1432. These three pivotal studies [58-60] of the multicentre interferon/ribavirin after combination therapy trials in IFN-naive as well as patients relapsing after interferon document the outstanding benefit of the combination as compared to interferon alone and identify which subgroups respond better according to virological and host factors prior to therapy. This combination does become the standard of care for chronic hepatitis C. The duration should be one year except for patients with favourable prognostic factors including low virus load and non-1 genotype.
61. 61 Xu Z-X, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects [Abstract]. Hepatology 1998; 28 (Suppl.):702.
62. 62 Blair CS, Davidson F, Lycett C, McDonald DM, Haydon GH, Yap PL, et al. Prevalence, incidence and clinical characteristics of hepatitis G virus/GB virus C infection in Scottish blood donors. J Infect Dis 1998; 178:1779-1782.
63. 63 Lin HH, Kao JH, Yah KY, Liu DP, Chang MH, Chen PJ, Chen DS. Mother-to-infant transmission of GB virus C/hepatitis G virus: the role of high-titered maternal viremia and mode of delivery. J Infect Dis 1998; 177:1202-1206.
64. 64 Parana R, Vitvitski L, Andrade Z, Trepo C, Cotrim H, Bertillon P, et al. Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Hepatology 1999; 30:289-293. This study does emphasize the prevalence and characteristics of unknown viruses responsible for acute and chronic hepatitis, especially in some areas.